Apellis Pharmaceuticals Inc. (APLS), which has demonstrated robust revenue growth from its rare disease drugs, Empaveli and Syfovre, is focused on enhancing the market potential of both drugs to achieve blockbuster status.
Empaveli, known generically as Pegcetacoplan, received its initial FDA approval in May 2021 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare, chronic, and potentially life-threatening blood disorder marked by persistently low hemoglobin levels, thrombosis, and debilitating symptoms.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.